A Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 1% and 3% Topical MIinocycline Gel (HY01) in Patients With Papulopustular Rosacea
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Minocycline (Primary)
- Indications Rosacea
- Focus Therapeutic Use
- Acronyms MARS
- Sponsors Hovione
- 02 Nov 2018 Planned End Date changed from 28 Sep 2018 to 1 May 2019.
- 02 Nov 2018 Planned primary completion date changed from 28 Sep 2018 to 1 Mar 2019.
- 02 Nov 2018 Status changed from recruiting to active, no longer recruiting.